Results 201 to 210 of about 2,781,261 (274)

Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment

, 2005
Thierry Dantoine, Sophie Auriacombe, Marie Sarazin, H. D. Becker, J.-J. Péré, I. Bourdeix   +5 more
openalex   +1 more source

Three New Cholinesterase-Inhibiting cis-Clerodane Diterpenoids from Otostegia limbata

, 2005
Viqar Uddin Ahmad, Afsar Khan, Umar Farooq, Farzana Kousar, Saleha Suleman Khan, Sarfraz Ahmad Nawaz, Muhammad Athar Abbasi, M. Iqbal Choudhary   +7 more
openalex   +2 more sources

EFNS‐ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease

European Journal of Neurology, 2015
R. Schmidt, E. Hofer, F. Bouwman, K. Buerger, C. Cordonnier, T. Fladby, D. Galimberti, J. Georges, M. Heneka, J. Hort, J. Laczó, J. Molinuevo, John T. O'Brien, D. Religa, D. Religa, P. Scheltens, J. Schott, S. Sorbi   +17 more
semanticscholar   +1 more source

Treating Vascular Dementia : Cholinesterase Inhibitors and …

Annals of Indian Academy of Neurology, 2004
Nagaraja D, Gangadhar B.N.
doaj  

Impact of cholinesterase-inhibitor insecticides on non-target wildlife: a review of studies relative to terrestrial vertebrates

, 2005
Olivier Lambert, Hervé Pouliquen, Philippe Clergeau   +2 more
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Natural cholinesterase inhibitors from marine organisms

Natural Product Reports, 2019
Covering: Published between 1974 up to 2018Inhibition of cholinesterases is a common approach for the management of several disease states. Most notably, cholinesterase inhibitors are used to alleviate the symptoms of neurological disorders like dementia
Tom Turk, Robert Frange, Lindon W K Moodie   +2 more
exaly   +2 more sources

An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease

Expert Opinion on Drug Safety, 2020
Introduction: Alzheimer’s disease (AD) is the most common cause of major neurocognitive disorders with a prevalence in the US of about 5.7 million in 2018.
A. Haake, Kevin L Nguyen, L. Friedman, Binu Chakkamparambil, G. Grossberg   +4 more
semanticscholar   +1 more source

Recent Advances in Virtual Screening for Cholinesterase Inhibitors.

ACS Chemical Neuroscience, 2020
Alzheimer's disease (AD) is a significant health crisis, and current treatments provide only limited benefits to cognition at the cost of serious side effects.
Jared A. Miles, Benjamin P. Ross
semanticscholar   +1 more source

Coumarins as cholinesterase inhibitors: A review.

Chemico-Biological Interactions, 2016
The first report in literature of the isolation of coumarin was in the year 1820. After this report, other papers were published demonstrating the isolation and synthesis of coumarin and analogues. These compounds have been studying along the years for several different pathologies.
Luana G. de Souza, Magdalena N Rennã, J. Figueroa-Villar   +2 more
semanticscholar   +4 more sources

Activity-guided isolation of cholinesterase inhibitors quercetin, rutin and kaempferol from Prunus persica fruit

Zeitschrift für Naturforschung C - A Journal of Biosciences, 2020
Prunus persica fruit is a source of anti-cholinesterase agents and led to an increase of acetylcholine levels in brain tissue as a usefull tool in the Alzheimer’s disease therapy.
D. Szwajgier, K. Borowiec, J. Zapp
semanticscholar   +1 more source